A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.
暂无分享，去创建一个
K. Gelmon | D. Ayers | L. Seymour | S. Chia | W. Walsh | L. McIntosh | J. A. Shabbits | K. Chi | D. Stewart | S. Janke | C. Cripps | S. Huan | D. Fry | L. Mcintosh